New combo therapy aims to tame ulcerative colitis faster and safer
NCT ID NCT06095596
First seen May 03, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests a new way to treat moderate to severe ulcerative colitis by using two drugs in sequence. First, a fast-acting drug (upadacitinib) is given for 8 weeks to quickly bring the disease under control, then patients switch to a safer long-term drug (vedolizumab) to keep symptoms away. The goal is to see if this approach works better than standard treatments. About 334 adults with active ulcerative colitis will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 501655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.